68 results found.
      
3Q13 Revenue: Anika Therapeutics
Orthobiologics $12.8MM, +39% (U.S. +26%) ORTHOVISC remains primary growth driver Claims #1 position in U.S. multi-injection segment Ex-U.S. viscosupplementation sales +83% YTD Strong MONOVISC, ORTHOVISC sales in Canada through ne...
2Q13 Revenue: Anika Therapeutics
Orthobiologic sales $16.5MM, +51% U.S. ORTHOVISC +49% Ex-U.S. S.r.l. orthobiologics flat (year-to-date +25%) Year-to-date ex-U.S. viscosupplementation +39%   U.S. biologics sales represent 65% to 80% of o...
BARE BONES® - July 31, 2013
Anika Therapeutics reported 2Q13 orthobiologic sales of US $16.5MM, +51% from 2Q12. (Anika Therapeutics, Inc., 7/31/13...
BARE BONES® - May 2, 2013
Anika Therapeutics reported 1Q13 orthobiologics sales of US $11.2MM, +12% from 1Q12. (
1Q13 Revenue: Anika Therapeutics
$11.2MM, +12% (U.S. +12%, ex-U.S. +9%) Growth reflects marketing and sales investments from partner, DePuy Mitek, to support awareness of ORTHOVISC Ex-U.S. viscosupplementation sales soft primarily due to reimbursement, country-specific issues ...
BARE BONES® - February 28, 2013
Anika Therapeutics reported 4Q12 orthobiologics revenue of US $19.6MM, +69% from 4Q11, and 2012 revenue of $49.9MM, +28% from 2011. (
4Q12 and 2012 Revenue: Anika Therapeutics
$49.9MM, +28% (U.S. ORTHOVISC +42%; ex-U.S. ORTHOVISC -17%) 4Q12 revenue: $19.6MM, +69% Extended DePuy agreement for U.S. distribution of ORTHOVISC through 2018 Negotiated distribution and clinical trial reimbursement agreement for ORTHOVI...
3Q12 Earnings: Anika Therapeutics
Orthobiologics $9.2MM, -11% ORTHOVISC sales -$1.1MM from 3Q11: temporary scale-up issue at Bedford manufacturing facility prevented the filling of some ORTHOVISC orders; will fill all delayed orders in 4Q U.S. ORTHOVISC demand continues to grow ...
BARE BONES® - October 31, 2012
Anika Therapeutics reported 3Q12 orthobiologics sales of US $9.2MM, -11% from 3Q11. (Anika Therapeutics, Inc., 10/30/1...
2Q12: A First Look at Earnings
ORTHOWORLD’s estimates place preliminary 2Q12 market growth at 5% over 2Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 2Q12, unless otherwise noted. Exhibit 1 Orthopaedic Sales Increas...
BARE BONES® - August 1, 2012
Anika Therapeutics reported 2Q12 orthobiologics sales of US $10.9MM, +12% from 2Q11. (An...
First Look at Quarterly Results: 1Q12 vs. 1Q11
ORTHOWORLD’s preliminary estimates place overall 1Q12 market growth at 3% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhibit 1 Orthopaedic Sales1 Increase...
BARE BONES® - May 4, 2012
Anika Therapeutics reported 1Q12 orthobiologics sales of US $10.1MM, +26% from 1Q11. (
Continuing 2011 Results, Including AAOS Conference Highlights
The orthopaedic industry appears to be tilting its focus from implant materials and toward implant alignment and personalization, per analyst review of the 2012 meeting of the American Academy of Orthopaedic Surgeons (AAOS). On the floor and in recent earnings calls, companies noted observatio...
3Q11: A First Look at Financials - Anika Therapeutics
ANIKA THERAPEUTICS Orthobiologics $10.3MM, +35% (U.S. +28%, ex-U.S. +55%) * ORTHOVISC U.S. +28%, ex-U.S. +72% * MONOVISC ex-U.S. +3% * Resolved 2Q ex-U.S. backorder issue with ORTHOVISC * Added distributors in EU for Hyalograft C, H...
First Look at 2Q11 Results: Anika Therapeutics
ANIKA THERAPEUTICS Orthobiologics $9.7MM, +27% (U.S. +36%, ex-U.S. +36%) * ORTHOVISC U.S. +36%, ex-U.S. -22%; * MONOVISC ex-U.S. +29%
First Look at 1Q11 Results: Anika Therapeutics
ANIKA THERAPEUTICS Orthobiologics $8MM, +16% (ORTHOVISC U.S. +21%, ex-U.S. -10%; MONOVISC +45%) * MONOVISC performing well in Europe * Equipment problem delayed ~$0.3MM in U.S. ORTHOVISC shipments until 2Q * Still expects MONOVISC FDA clearan...
A Final Look at 2010 Results: Anika Therapeutics
ANIKA THERAPEUTICS Orthobiologics $30.7MM, +34% (ORTHOVISC U.S. +32%, ex-U.S. -8%; MONOVISC in EU +126%) 4Q10 revenue: $8.4MM, +40% (U.S. +25%, ex-U.S. +96%; ORTHOVISC U.S. +25%, ex-U.S. +21%) * Requested review of MONOVISC via FDA’s o...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group